ALK and non-small cell lung carcinoma: Both the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines and the National Comprehensive Cancer Network (NCCN) Guidelines for NSCLC recommend second- or third-generation ALKi as the preferred first-line treatment for patients with ALK rearrangements (3, 11).